Main Session
Sep
29
SS 24 - Head and Neck 2: Top-Rated Abstracts in Head & Neck Cancer
245 - Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and
Presenter(s)
Colette Shen, MD, PhD - University of North Carolina School of Medicine & Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina